DISCOUNT ZERTIFIKAT - NOVO NORDISK ADR B | Real-time Bid/Ask 12:08:31 2024-07-03 EDT | ||
| 91.47 EUR / 91.49 EUR | -0.66% |
|
| Current month | -0.17% | ||
| 1 month | +1.81% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-07-03 | 91.39 | -0.76% |
| 24-07-02 | 92.09 | -0.05% |
| 24-07-01 | 92.14 | -0.12% |
| 24-06-28 | 92.25 | +0.01% |
| 24-06-27 | 92.24 | -0.23% |
Delayed Quote Börse Stuttgart
Last update July 03, 2024 at 11:24 am
More quotesStatic data
| Product type | Discount-Zertifikate |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | Morgan Stanley |
| WKN | ME79EL |
| ISIN | DE000ME79EL5 |
| Date issued | 2024-01-22 |
| Maturity | 2024-09-20 (79 Days) |
| Parity | 1 : 1 |
| Emission price | 85.19 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 92.45 € |
|---|---|
| Lowest since issue | 82.38 € |
| Spread | 0.03 € |
| Spread % | 0.03% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
993.5
DKK
Average target price
952.2
DKK
Spread / Average Target
-4.16%
- Stock Market
- Certificates
- Certificat
